COVID-19 Protective Immunity Study – Recruitment Literature (Printed Copy)

Have you recovered from COVID-19? We Need Your Help.

COVID-19 infection imposes significant societal and health burdens. Discovering therapeutic/diagnosis antibodies and developing an effective vaccine would have broad implications for global public health. Your convalescent plasma, which contains antibodies against the virus, could also save a life.

Researchers at Dana-Farber Cancer Institute have launched an initiative to help determine how a person’s immune response to COVID-19 is affected by their age, medical history and genetics. They are also interested in determining if you are an elite responder who produces exceptionally high levels of protective antibodies against COVID-19.

Am I eligible?

We are enrolling 150 volunteers who have recovered from COVID-19 (i.e. resolution of fever, improvement of respiratory symptoms and 2 negative COVID-19 NP tests >24 hours apart) and will be broadly assigned into one of the following three groups.

Group 1 – Healthcare workers who have directly cared for COVID-19 infected individuals (e.g. ER, clinic, other).

Group 2 – Cancer patients that are at any stage of their cancer illness. Most importantly if you have undergone recent chemo or radiation therapy or immunotherapy.

Group 3 - Individuals who believe they have acquired COVID-19 infection by a route other than direct COVID-19 patient exposure. This group includes physicians and healthcare workers who have no known COVID-19 patient contacts and individuals in the community that have recovered from COVID-19.

What do I need to do?
Joining the COVID-19 Protective Immunity Study is simple. Click this link (https://j.mp/3flblXr) to let us know you are interested and leave your contact information so the research nurse can contact you for consent and eligibility screening.

Remote Consent and on study Review

- During the phone call, the research nurse will review the consent form with you
- You will have the opportunity to ask any questions you may have.
- The research nurse will send a copy of the consent form via email, fax or USPS mail.
If sent via email, the participant should print and sign/date the consent form and scan/email the consent form back to the research nurse email address.

If sent via fax, the participant should sign/date the consent form and fax the consent form back to the research nurse’s provided fax number.

If sent via USPS mail, the participant will sign/date the consent form on the day they receive the consent form and bring it with them at the time of their appointment if they are eligible.

Once you have provided consent, the research nurse will work with you by phone to complete an online eligibility survey hosted on a HIPPA-compliant server to determine if you meet the requirements to participate in this study. This information will be related to your COVID-19 experience and include information related to your health history.

- If you do not meet the requirements to join the study, the research nurse will thank you for your time and you will no longer be contacted by the study team.
- If you do meet the requirements to join the study, the research nurse will set up an appointment for a follow-up questionnaire completion and a visit to the Dana-Farber Cancer Institute (DFCI) for a blood draw.

- Your projected time at DFCI will be approximately 0.5 hour.
- You will also be asked to provide a one-time collection of 4 tablespoons of blood via blood draw.

**Is there any compensation for participating?**

Onsite parking and a one-time compensation payment will be arranged for you upon completing your blood draw.

**Where can I find more information?**

Access this website ([https://j.mp/3flblXr](https://j.mp/3flblXr)) and answer the three questions and a research nurse will contact you with more information.

**Who is leading this study?**

Dana-Farber Cancer Institute

Wayne A. Marasco, MD, Ph.D.,
Professor, Department of Cancer Immunology and Virology

_________________________________________

Dana Farber

IRB NUMBER: 20-201

IRB APPROVAL DATE: 05/26/2020